Table 1.

Transition probabilities, costs, and utilities in this study.

Category	Base-case	Lower	Upper	Distribution	Reference
Cure rate
Vancomycin	87.5%	81.6%	93.4%	Beta (α:105, β:15)	(21–23)
Vancomycin (IBD)	78.6%	57.1%	99%	Beta (α: 11, β: 3)	(24)
FMT	90.5%	84.2%	96.8%	Beta (α: 76, β: 8)	CGMTC
FMT (IBD)	87.5%	76%	99%	Beta (α: 28, β: 4)	CGMTC
Fidaxomicin	89.7%	83.3%	96.1%	Beta (α: 79, β: 9)	(21, 22)
Fidaxomicin (IBD)	81.3%	69.6%	93%	Beta (α: 35, β: 8)	(25, 26)
Recurrence rate
Vancomycin	31.0%	24.8%	38.2%	Beta (α: 32, β: 72)	(21–23)
Vancomycin (IBD)	45.5%	16.1%	74.9%	Beta (α: 5, β: 6)	(24)
FMT	9.21%	2.71%	15.7%	Beta (α: 7, β: 69)	CGMTC
FMT (IBD)	27.0%	10.6%	43.4%	Beta (α: 5, β: 14)	CGMTC
Fidaxomicin	20.3%	11.4%	29.2%	Beta (α: 16, β: 63)	(21, 22)
Fidaxomicin (IBD)	22.8%	8.9%	36.7%	Beta (α: 8, β: 27)	(25, 26)
Crude mortality rate (3 m)	0.2%	fixed	fixed	fixed	Local data
Mortality from CDI	0.7%	0.2%	1.2%	Beta (α:12, β:1,724)	(12, 27)
Utility
Improve	1	Fixed	Fixed	Fixed	-
Dead	0	Fixed	Fixed	Fixed	-
Recurrent CDI	0.82	0.72	0.84	Triangular (0.82, 0.72, 0.84)	(11, 28, 29)
Refractory CDI	0.71	0.5	0.72	Triangular (0.71,0.50,0.72)	(11, 28, 29)
Cost
Vancomycin	25,160	18,870	31,450	Gamma (25, 160, SD: 3,145)	Local cost
FMT	67,000	50,250	83,750	Gamma (67,000, SD: 8,375)	Local cost
FMT (recurrence)	67,286	50,465	84,108	Gamma (67,286, SD: 8,411)	Local cost
Fidaxomicin	21,627	16,220	27,034	Gamma (21,627, SD: 2,703)	Local cost

CGMTC, Chang Gung Microbiota Therapy Center; CDI, Clostridioides difficile infection; FMT, fecal microbiota transplantation; IBD, inflammatory bowel disease; SD, standard deviation.

The costs of vancomycin, fidaxomicin, FMT via colonoscopy, and the costs of the ward, registration, diagnostic, medicine service, and nursing fees were included in this analysis.

All costs are expressed in New Taiwan Dollars (NT$).